Cleared Traditional

K060204 - LIAISON EA IGG

K060204 is the FDA 510(k) clearance for LIAISON EA IGG by DiaSorin, Inc.. It is a Class 1 Microbiology device (product code LSE) cleared through the Traditional 510(k) pathway after a 265-day FDA review.

K060204 · DiaSorin, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2006
Decision
265d
Days
Class 1
Risk

K060204 is an FDA 510(k) clearance for the LIAISON EA IGG. Classified as Epstein-barr Virus, Other (product code LSE), Class I - General Controls.

Submitted by DiaSorin, Inc. (Stillwater, US). The FDA issued a Cleared decision on October 18, 2006 after a review of 265 days - an extended review cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3235 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all DiaSorin, Inc. devices

Submission Details

510(k) Number K060204 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 26, 2006
Decision Date October 18, 2006
Days to Decision 265 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review Yes - reviewed by an FDA-accredited third party
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
163d slower than avg
Panel avg: 102d · This submission: 265d
Pathway characteristics
Predicate-based equivalence. Third-party reviewed.

Device Classification

Product Code LSE Epstein-barr Virus, Other
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 866.3235
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.

Regulatory Consultant

Tuv America, Inc.

The regulatory consultant manages the 510(k) submission process on behalf of the applicant - coordinating technical documentation, predicate strategy and FDA communications. Identifying the consultant behind a submission is a key signal for competitive regulatory intelligence.

Regulatory Peers - LSE Epstein-barr Virus, Other

All 23
Devices cleared under the same product code (LSE) and FDA review panel - the closest regulatory comparables to K060204.
LIAISON® EA IgG and LIAISON® EA IgG Serum Control Set
K162959 · DiaSorin, Inc. · Jan 2017
BIOPLEX 2200 EBV IGG PANEL FOR BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM
K062211 · Bio-Rad Laboratories, Inc. · Dec 2006
BIOPLEX 2200 EBV IGM PANEL ON BIOPLEX 2200 MULTI-ANALYTE DETECTION SYSTEM
K062213 · Bio-Rad Laboratories, Inc. · Dec 2006
ETI-EA-G ASSAY
K992191 · DiaSorin, Inc. · Jul 1999
COPALIS MULTIPLEX EBV ANTIBODY ASSAY
K991660 · DiaSorin, Inc. · Jun 1999
EBV-VCA IGG ELISA TEST SYSTEM
K981812 · Diamedix Corp. · Mar 1999